TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04869540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Evidence based care for transition-aged youth (TAY) with ASD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'Got Transition' toolkit and resources
Description: Providers will be trained in the 'Got Transition' toolkit (the systems level component of the intervention) and have access to web-based transition resources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Got Transition' toolkit and resources
Description: Providers will be trained in the 'Got Transition' toolkit (the systems level component of the intervention) and have access to web-based transition resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSE intervention
Description: A family-based problem solving education (PSE) intervention.
Study: NCT04603261

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast concentration in urine
Description: Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast concentration in urine
Description: Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast concentration in urine
Description: Iodinated contrast content of urine samples, collected post-contrast over a period of 5 days at all times of natural excretion within that period, will be assayed.~Serum creatinine will be measured daily before (day 0) and during 5 days post-contrast, and again at 1 month post-contrast.
Study: NCT04800458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: * Thrombopoietin : 7 ml whole blood.~* Anti-platelet antibodies free : 14 ml whole blood.~* Anti-platelet antibodies bound :~If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation.
Study: NCT04950465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensodyne Sensitivity & Gum
Description: Sensodyne Sensitivity \& Gum toothpaste containing 0.454% SnF2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection Fresh Lime
Description: Crest Cavity Protection Fresh Lime is containing 1150 parts per million fluoride as Sodium fluoride.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Repair and Protect
Description: Sensodyne Repair and Protect dentifrice containing 5.0% weight/weight calcium sodium phosphosilicate.
Study: NCT04855643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based active tDCS
Description: Anode and cathode electrodes will be placed over the left and right dorsolateral prefrontal cortexes, respectively, with the use of the Omni-Lateral-Electrode system. Caregivers will set up and administer tDCS for participants with ADRD at home. tDCS will be applied for 30 min at an intensity of 2mA, with 30 s ramping up and down. All sessions will be remotely supervised by trained research staff.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: home-based sham tDCS
Description: For sham stimulation, electric current will be applied only in the first 30s tDCS. All sessions will be remotely supervised by trained research staff.
Study: NCT06581510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esthetic dental crowns
Description: Minimal Preparation of esthetic dental crown

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esthetic dental crowns
Description: Minimal Preparation of esthetic dental crown

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: Nuu smile ready-made zirconia crown with its well-known reduction
Study: NCT06582069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bleaching
Description: Bleaching

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bleaching
Description: Bleaching

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bleaching
Description: Bleaching

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bleaching
Description: Bleaching
Study: NCT06582004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CH2 vaginal gel
Description: The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hyaluronic acid gel
Description: The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
Study: NCT05848895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic Manipulative Treatment is a manual treatment therapy applied by licensed physicians that consists of using ones hands to improve the structure and function of the body. In this situation it will involve gentle and passive modalities that are well-tolerated by infants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Repositioning
Description: Parents will receive standardized handouts/materials instructing on repositioning intended to help improve head shape in infants with plagiocephaly.
Study: NCT06369974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antisense oligonucleotide treatment (ASO)
Description: Drug: nL-TUBB4-001; Personalized antisense oligonucleotide
Study: NCT05279287

Intervention type: OTHER
Intervention: Video and kinematic data recording of minimally invasive surgical procedure
Description: Analysis of video and kinematic data through validated methodology in order to analyse technical performance and errors enacted intraoperatively.
Study: NCT05749549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1733
Description: Subjects will receive oral administration of BR1733.
Study: NCT05676307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: Cawthorne Cooksey Based Vestibular Rehabilitation Exercises (Oculomotor exercise, Vestibulo-ocular Exercise, posture exercise, balance training, etc)
Study: NCT05742607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH5201 + durvalumab + standard chemotherapy
Description: Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab.
Study: NCT06096506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Culinary Medicine
Description: The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($30 per class = $150 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions
Study: NCT05982847

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure screening
Description: Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure screening
Description: Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
Study: NCT04978584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT06175481

Intervention type: OTHER
Intervention: Popliteal Vein Compliance
Description: Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).

Intervention type: OTHER
Intervention: Popliteal Vein Compliance
Description: Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).
Study: NCT05523544

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: schematherapy
Description: psychotherapy
Study: NCT06473220

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Narrative nursing
Description: Narrative nursing is an intervention mode of psychological nursing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative nursing
Description: Narrative nursing is an intervention mode of psychological nursing.
Study: NCT06021067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Death mesenchymal stem cell
Description: A standard treatment regimen combined with a pre-specified starting dose of dead mesenchymal stem cells (2.0×10\^7 for 60kg patient), infusion every 3 days, continuous infusion 4 times, treatment duration is 4\~6 weeks.
Study: NCT04782778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 1 mg/kg Bupivacaine (0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 1 mg/kg Bupivacaine (0.25%)
Study: NCT05976919

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function testing
Description: Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function testing
Description: Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function testing
Description: Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function testing
Description: Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function testing
Description: Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
Study: NCT05909371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Application of two different exercises to liver transplant individuals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Application of two different exercises to liver transplant individuals.
Study: NCT05627635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo a blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo a blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo a blood sample collection
Study: NCT01010724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bIAP
Study: NCT05627635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study: NCT01010724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05547516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard infusion chemotherapy
Description: standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard infusion chemotherapy
Description: standard infusion chemotherapy (including gemcitabine, mitomycin, epirubicin, etc.), dissolved in 50mL normal saline or glucose, intravesical infusion chemotherapy, retained for 60min. Perfusion can be performed within 24 hours after surgery, and then once a week for a total of 8 times, and then once a month until 12 months after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BL - 5 ala PDT
Description: BL - 5 ala PDT - plan: 5ALA 1.5g (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd), dissolved in 50mL normal saline, was infused into the bladder for 2 hours before surgery and before each cystoscopy. Blue laser irradiation was performed under a flexible cystoscope at 30mW/cm2 for 21min. PDT was performed during the operation and at 3, 6, and 9 months after the operation.
Study: NCT05957939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkaline Glucosodiene Molecules
Description: Toxic chemotherapeutic nutrition of cancer cells by alkaline glucosodiene molecules via targeting metabolic of cancerous tumors: a promising treatment
Study: NCT05627635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT05994729

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive Physiological Assessment of Coronary Circulation
Description: After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.
Study: NCT06273176

Intervention type: PROCEDURE
Intervention: Awake mapping under local anesthesia
Description: During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.

Intervention type: PROCEDURE
Intervention: Asleep mapping under general anesthesia
Description: During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.

Intervention type: PROCEDURE
Intervention: Resection under general anesthesia without mapping
Description: During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.
Study: NCT05720325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupixent is an interleukin-4 receptor alpha antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupixent is an interleukin-4 receptor alpha antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: House Dust Mites (HDM)
Description: House Dust Mites used to challenge subjects using an aeroallergen challenge chamber

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: House Dust Mites (HDM)
Description: House Dust Mites used to challenge subjects using an aeroallergen challenge chamber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: House Dust Mites (HDM)
Description: House Dust Mites used to challenge subjects using an aeroallergen challenge chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: House Dust Mites (HDM)
Description: House Dust Mites used to challenge subjects using an aeroallergen challenge chamber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo administered to placebo arms of study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo administered to placebo arms of study.
Study: NCT04978584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT05374811

Intervention type: OTHER
Intervention: Neuropathic Pain
Description: Neuropathic pain degrees of the patients will be evaluated with the Douleur Neuropathic-4 (DN4) questionnaire.
Study: NCT05476562

Intervention type: OTHER
Intervention: Tyrosine Kinase Inhibitors (TKIs)
Description: The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.

Intervention type: OTHER
Intervention: Tyrosine Kinase Inhibitors (TKIs)
Description: The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.

Intervention type: OTHER
Intervention: Tyrosine Kinase Inhibitors (TKIs)
Description: The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.

Intervention type: OTHER
Intervention: Tyrosine Kinase Inhibitors (TKIs)
Description: The study included patients with CML who were previously treated with TKIs, who are relapsed/refractory to/intolerant of TKIs on third or later lines of therapy in the US.
Study: NCT05322187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
Study: NCT06210529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a high-intensity focused ultrasound tumor treatment system (Super Knife)
Description: All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a high-intensity focused ultrasound tumor treatment system (Super Knife)
Description: All participants will be randomly divided into groups A and B. Participants in group A will receive a high-intensity focused ultrasound tumor treatment (Super Knife) once, and participants in group B will receive treatment twice (4 weeks, one cycle).. Breast cancer surgery was performed at 3 months ± 1 week after the Super Knife treatment.